Published by Benjamin Chiou on 3rd July 2026
(Sharecast News) - AIM-listed Craneware has said it expects its full-year results to be below market expectations due to the timing of the 340B drug pricing programme in the US and the deferral of several contracts.
URL: http://www.digitallook.com/dl/news/story/36049113/...